Bevacizumab plus folfiri as first-line therapy in advanced colorectal cancer: A multicenter phase II study of the gruppo oncologico dell' italia meridionale (Prot. Goim 2601)

被引:0
|
作者
Giuliani, F.
De Vita, F. [1 ]
Lorusso, V.
Maiello, E.
Orditura, M. [1 ]
Nugnes, I.
Leo, S.
Catalano, G. [1 ]
Colucci, G.
机构
[1] Univ Naples 2, Med Oncol Unit, Naples, Italy
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:20 / 21
页数:2
相关论文
共 50 条
  • [1] Bevacizumab plus FOLFIRI as first-line treatment in advanced colorectal cancer (ACC): A multicenter phase II study of the gruppo oncologico dell' Italia meridionale (prot. goim 2601)
    Giuliani, F.
    Lorusso, V
    De Vita, F.
    Cinieri, S.
    Maiello, E.
    Nugnes, I
    Del Prete, S.
    Orditura, M.
    Leo, S.
    Addeo, R.
    Colucci, G.
    ANNALS OF ONCOLOGY, 2008, 19 : 96 - 96
  • [2] BEVACIZUMAB plus FOLFIRI AS FIRST-LINE TREATMENT IN ADVANCED COLORECTAL CANCER (ACC): A MULTICENTER PHASE II STUDY OF THE GRUPPO ONCOLOGICO DELL' ITALIA MERIDIONALE (PROT. GOIM 2601)
    Giuliani, F.
    Lorusso, V.
    De Vita, F.
    Cinieri, S.
    Maiello, E.
    Nugnes, I.
    del Prete, S.
    Orditura, M.
    Leo, S.
    Addeo, R.
    Colucci, G.
    EJC SUPPLEMENTS, 2008, 6 (14): : 121 - 121
  • [3] Bevacizumab plus folfiri as first-line treatment in advanced colorectal cancer (ACC): A multicenter phase II study of the Gruppo Oncologico dell'Italia Meridionale (prot. GOIM 2601)
    Colucci, G.
    Giuliani, F.
    Lorusso, V.
    De Vita, F.
    Cinieri, S.
    Maiello, E.
    Nugnes, I.
    Del Prete, S.
    Orditura, M.
    Leo, S.
    Addeo, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [4] Bevacizumab plus folfiri as first-line therapy in advanced colorectal cancer: A multicenter phase II study of the gruppo oncolgico dell' italia meridionale (prot. goim 2601)
    Giuliani, F.
    De Vita, F.
    Lorusso, V
    Maiello, E.
    Orditura, M.
    Nugnes, I
    Leo, S.
    Catalano, G.
    Colucd, G.
    ANNALS OF ONCOLOGY, 2007, 18 : 188 - 188
  • [5] FOLFIRI VERSUS XELIRI IN UNTREATED ADVANCED COLORECTAL CANCER: A PHASE II RANDOMISED TRIAL OF THE GRUPPO ONCOLOGICO DELL' ITALIA MERIDIONALE (PROT. GOIM 2405)
    Giuliani, R.
    De Vita, F.
    Maiello, E.
    Nugnes, I.
    Di Bisceglie, M.
    Romito, S.
    Lorusso, V.
    Catalano, G.
    Agostara, B.
    Colucci, G.
    EJC SUPPLEMENTS, 2008, 6 (14): : 120 - 121
  • [6] Folfiri vs xeliri in untreated advanced colorectal cancer: A phase II randomised trial of the gruppo oncologico dell'italia meridionale (Prot. Goim 2405)
    Colucci, G.
    Giuliani, F.
    De Vita, F.
    Di Bisceglie, M.
    Maiello, E.
    Romito, S.
    Caruso, M.
    Catalano, G.
    ANNALS OF ONCOLOGY, 2007, 18 : 22 - 23
  • [7] FOLFIRI regimen in advanced colorectal cancer: the experience of the Gruppo Oncologico dell'Italia Meridionale (GOIM)
    Maiello, Evaristo
    Gebbia, V.
    Guiliani, F.
    Paoletti, G.
    Gebbia, N.
    Borsellino, N.
    Carteni, G.
    Pezzella, G.
    Manzione, L.
    Romito, S.
    Lopez, M.
    Colluci, G.
    ANNALS OF ONCOLOGY, 2005, 16 : 56 - 60
  • [8] FOLFIRI with or without celecoxib in advanced colorectal cancer: a randomized phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM)
    Maiello, E.
    Giuliani, F.
    Gebbia, V.
    Di Renzo, N.
    Pezzella, G.
    Romito, S.
    Mallamaci, R.
    Lopez, M.
    Colucci, G.
    ANNALS OF ONCOLOGY, 2006, 17 : VII55 - VII59
  • [9] Folfiri plus Bevacizumab as First-Line Treatment in Advanced Colorectal Cancer (ACC): Final Results (PROT. GOIM 2601)
    Giuliani, F.
    De Vita, F.
    Lorusso, V.
    Cinieri, S.
    Nugnes, I.
    Maiello, E.
    Del Prete, S.
    Orditura, M.
    Leo, S.
    Colucci, G.
    ONCOLOGY, 2009, 77 : 147 - 147
  • [10] FOLFIRI plus bevacizumab as first-line treatment in advanced colorectal cancer (ACC): Final results (prot. GOIM 2601)
    Giuliani, F.
    De Vita, F.
    Lorusso, V.
    Cinieri, S.
    Nugnes, I.
    Orditura, M.
    Maiello, E.
    Del Prete, S.
    Leo, S.
    Colucci, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)